In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations ...

In major diabetes research news just published in Nature Communications, scientists at the Diabetes Research Institute (DRI) at the University of Miami have shown that a small peptide, called THR-123, ...

A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Although ‘lean type 2 diabetes’ is not uncommon, clinicians must first exclude other causes including autoimmune, monogenic, ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight loss ...

Innovative stem cell therapy shows promise in restoring insulin production for severe type 1 diabetes patients.

Learn what Type 1 diabetes is how it differs from other forms of diabetes and what causes it Understand key symptoms early ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased ...

Pharmaceutical Executive recently spoke with RheumaGen CEO Richard Freed about his career and the work the biotech is doing ...

MIT researchers have developed an implant that releases glucagol under the control of external sensors to protect diabetes ...